Mikati Abdul G, Khanna Omaditya, Zhang Lingjiao, Girard Romuald, Shenkar Robert, Guo Xiaodong, Shah Akash, Larsson Henrik B W, Tan Huan, Li Luying, Wishnoff Matthew S, Shi Changbin, Christoforidis Gregory A, Awad Issam A
Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, The University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
Brain Research Imaging Center, The University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA.
J Cereb Blood Flow Metab. 2015 Oct;35(10):1632-9. doi: 10.1038/jcbfm.2015.98. Epub 2015 May 13.
Patients with the familial form of cerebral cavernous malformations (CCMs) are haploinsufficient for the CCM1, CCM2, or CCM3 gene. Loss of corresponding CCM proteins increases RhoA kinase-mediated endothelial permeability in vitro, and in mouse brains in vivo. A prospective case-controlled observational study investigated whether the brains of human subjects with familial CCM show vascular hyperpermeability by dynamic contrast-enhanced quantitative perfusion magnetic resonance imaging, in comparison with CCM cases without familial disease, and whether lesional or brain vascular permeability correlates with CCM disease activity. Permeability in white matter far (WMF) from lesions was significantly greater in familial than in sporadic cases, but was similar in CCM lesions. Permeability in WMF increased with age in sporadic patients, but not in familial cases. Patients with more aggressive familial CCM disease had greater WMF permeability compared to those with milder disease phenotype, but similar lesion permeability. Subjects receiving statin medications for routine cardiovascular indications had a trend of lower WMF, but not lesion, permeability. This is the first demonstration of brain vascular hyperpermeability in humans with an autosomal dominant disease, as predicted mechanistically. Brain permeability, more than lesion permeability, may serve as a biomarker of CCM disease activity, and help calibrate potential drug therapy.
患有家族性脑海绵状血管畸形(CCM)的患者CCM1、CCM2或CCM3基因单倍体不足。相应CCM蛋白的缺失在体外以及在小鼠脑内的活体中会增加RhoA激酶介导的内皮通透性。一项前瞻性病例对照观察性研究调查了家族性CCM患者的大脑与无家族性疾病的CCM病例相比,是否通过动态对比增强定量灌注磁共振成像显示血管通透性增加,以及病灶或脑血管通透性是否与CCM疾病活动相关。家族性病例中远离病灶的白质(WMF)通透性显著高于散发性病例,但CCM病灶中的通透性相似。散发性患者中WMF的通透性随年龄增加,而家族性病例中则不然。与疾病表型较轻的患者相比,患有侵袭性更强的家族性CCM疾病的患者WMF通透性更高,但病灶通透性相似。因常规心血管适应症接受他汀类药物治疗的受试者WMF通透性有降低趋势,但病灶通透性无此趋势。正如机制预测的那样,这是首次在患有常染色体显性疾病的人类中证明脑血管通透性增加。脑通透性而非病灶通透性可能作为CCM疾病活动的生物标志物,并有助于校准潜在的药物治疗。